A Phase 3 interventional study of Carisoprodol SR and Carisoprodol SR in Lower Back Pain, sponsored by Meda Pharmaceuticals. Completed at 68 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-11-09.
Sponsored by Meda Pharmaceuticals · Phase 3, Interventional, and Treatment
The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.
Methodology:
This was a randomized, double-blind, double-dummy, placebo-controlled, parallel-group study in subjects 18-70 years of age with acute, painful, muscle spasm of the lower back. The study consisted of a baseline screening (Study Day 1), during which subjects were evaluated for inclusion/exclusion criteria, and a 7-day double-blind treatment period (Study Day 1 through Study Day 7). Subjects were randomly assigned to be dosed twice daily with one of the following double-blind treatments: sustained release(SR) carisoprodol 500-mg tablets,sustained release (SR) carisoprodol 700-mg tablets, or placebo.
Subjects were evaluated in the clinic on Study Days 1, 3 and 7. Subjects who remained symptomatic on Study Day 7 were allowed to continue in the study for a 7-day, double-blind extension period at the discretion of the Investigator. Subjects were contacted by telephone for a safety follow-up 7 days after the last dose of study medication.
A pharmacokinetic (PK) substudy was conducted at selected sites. These sites obtained blood samples for PK analysis at the end of the 7-day treatment period and the 14-day treatment period, if applicable.
2,818 studies on the registry are indexed under Low Back Pain; 482 are open to participants now.
This study's enrollment of 840 is above the median of 60 across 2,268 interventional studies indexed under Low Back Pain.
Browse Low Back Pain studies →Meda Pharmaceuticals is the lead sponsor of 19 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
tablet sustained release (SR)
Drug: Carisoprodol SR
sustained release(SR) tablet
Drug: Carisoprodol SR
tablet
Drug: Placebo
700 mg twice daily
Also known as: sustained release(SR)
500 mg twice daily
Also known as: sustained release(SR) tablet
Placebo tablet
Also known as: no other name
Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)
the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit
Time frame: up to 14 days
Subject Functional Assessment Based on the Roland-Morris Disability Questionnaire (RMDQ)
Time frame: up to 14 days
Adverse Event Assessment
the number of adverse events reported during the course of the study as reported by the participants
Time frame: up to 21 days
| Milestone | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet |
|---|---|---|---|
| Started | 281 | 280 | 279 |
| Completed | 242 | 241 | 252 |
| Not completed | 39 | 39 | 27 |
the scale used was from 0 to 100 mm. 0 equaled no pain and 100 equaled maximum pain.participants measure their pain before treatment and during treatment at each visit
| mm | Carisoprodol 500mg Tablets | Carisoprodol 700mg Tablets | Placebo Tablets |
|---|---|---|---|
| Subject Rating of Pain on a 100-point Visual Analog Scale (VAS) | 27.5 (-21 to 83) | 28 (-19 to 89) | 28.6 (-36 to 82) |
Results for this outcome have not been posted.
the number of adverse events reported during the course of the study as reported by the participants
Results for this outcome have not been posted.
Collected over up to 21 days. Non-serious events are listed at a 0.7% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carisoprodol 700mg | — | 0/278 (0%) | 78/278 (28.1%) |
| Carisoprodol 500mg Tablet | — | 1/280 (0.4%) | 65/280 (23.2%) |
| Placebo Tablet | — | 0/275 (0%) | 37/275 (13.5%) |
| Event | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet |
|---|---|---|---|
| transient ischemic attackCardiac disorders | 0/278 | 1/280 | 0/275 |
| Event | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet |
|---|---|---|---|
| somnolenceNervous system disorders | 44/44 | 36/280 | 18/275 |
| dizzinessNervous system disorders | 23/278 | 12/280 | 6/275 |
| nauseaGastrointestinal disorders | 5/278 | 12/280 | 6/275 |
| headacheGeneral disorders | 8/278 | 4/280 | 5/275 |
| fatigueGeneral disorders | 5/278 | 5/280 | 2/275 |
| Age, Categorical(Participants) | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 278 | 278 | 275 | 831 |
| >=65 years | 3 | 2 | 4 | 9 |
| Age Continuous(years) | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet | Total |
|---|---|---|---|---|
| Mean | 40.3 ± 13.05 | 41.4 ± 12.6 | 40.9 ± 12.72 | 40.9 ± 12.78 |
| Sex: Female, Male(Participants) | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet | Total |
|---|---|---|---|---|
| Female | 133 | 144 | 136 | 413 |
| Male | 148 | 136 | 143 | 427 |
| Region of Enrollment(participants) | Carisoprodol 700mg | Carisoprodol 500mg Tablet | Placebo Tablet | Total |
|---|---|---|---|---|
| United States | 281 | 280 | 279 | 840 |
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Meda Pharmaceuticals